Gilead Sciences (NASDAQ:GILD – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of -0.650–0.300 for the period, compared to the consensus estimate of -0.790. The company issued revenue guidance of $30.1 billion-$30.4 billion, compared to the consensus revenue estimate of $30.5 billion.
Analyst Ratings Changes
Several analysts recently commented on the company. Truist Financial dropped their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Royal Bank Of Canada decreased their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $133.00 to $155.00 in a report on Monday, July 6th. Wall Street Zen lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Daiwa Securities Group reduced their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $157.93.
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.26) by $0.51. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the company posted $2.01 earnings per share. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences will post -0.78 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently 44.69%.
Insider Activity
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 82,000 shares of company stock valued at $10,641,790. Insiders own 0.30% of the company’s stock.
Key Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, up 10.6% year over year and above the $7.4 billion consensus estimate. The adjusted loss of $6.75 per share was narrower than analysts’ expected loss of approximately $7.07–$7.26. Gilead Reports Q2 Loss, Beats Revenue Estimates
- Positive Sentiment: Management said base-business growth was the strongest in three years. HIV product sales rose at a double-digit rate, PrEP sales reportedly doubled to about $1 billion, and newer products including Yeztugo and oncology drug Trodelvy are gaining traction. Gilead also raised its full-year HIV growth outlook to 9%–10%. Gilead Raises HIV Growth Outlook
- Positive Sentiment: Cantor Fitzgerald reaffirmed its “overweight” rating with a $155 price target, while Needham maintained a “buy” rating and a $170 target. Gilead also declared its regular $0.82 quarterly dividend, supporting the stock’s income appeal. Analyst Ratings and Price Targets
- Neutral Sentiment: Fiscal 2026 EPS guidance of a $0.65–$0.30 loss is better than the consensus estimate for a $0.79 loss, but revenue guidance of $30.1 billion–$30.4 billion is slightly below the $30.5 billion forecast. The outlook reflects acquisition-related costs and continued investment.
- Negative Sentiment: Gilead swung to a quarterly loss from year-ago earnings of $2.01 per share, largely because of costs tied to recent acquisitions and higher R&D spending. The company also widened its projected 2026 operating loss. Gilead Second-Quarter Sales Rise
- Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment. This decline underscores pressure on a legacy product. Gilead Swings to Loss on R&D Costs
- Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 plan. Because he retained more than 592,000 shares, the transaction is a limited negative signal.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $26,000. Swiss RE Ltd. bought a new stake in shares of Gilead Sciences in the fourth quarter worth $31,000. Mcguire Capital Advisors Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $43,000. Finally, Acumen Wealth Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter valued at about $46,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
- Is ADM’s Rally Getting Ahead of Its Policy Tailwind?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
